Aprea Therapeutics (APRE) Price & Analysis

Compare

486 Followers

APRE Stock Chart & Stats

$0.91

-$0.03(-0.72%)

At close: Jan 08 4:00 PM EST

$0.91

-$0.03(-0.72%)

Day’s Range― - ―

52-Week Range$0.90 - $5.00

Previous CloseN/A

Volume2.88K

Average Volume (3M)55.77K

Market Cap

$5.74M

Enterprise Value-$5.52M

Total Cash (Recent Filing)$13.72M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.81

Next Earnings

Mar 26, 2026

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding6,310,673

10 Day Avg. Volume84,633

30 Day Avg. Volume55,770

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.94

Price to Sales (P/S)12.06

P/FCF Ratio-1.34

Enterprise Value/Market Cap-0.96

Enterprise Value/Revenue-11.31

Enterprise Value/Gross Profit0.88

Enterprise Value/Ebitda0.40

Forecast

1Y Price Target

$7.50

Price Target Upside724.18% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe safety and toxicity profile of Aprea's programs remain favorable, which is crucial for the continuation and advancement of their clinical trials.

Drug EfficacyAPR-1051 demonstrated stable disease in several patients and is advancing to higher dosing cohorts, showing promising efficacy signals.

Strategic DevelopmentAprea is actively exploring combination studies with other agents, which could enhance the therapeutic efficacy of their cancer treatments.

Bears Say

Industry ChallengesIssues in the synthetic lethality space, particularly for companies like Repare and Zentalis, cast a shadow over Aprea.

Stock PerformanceAprea's share price has pulled back to near an all-time low, driven by factors unrelated to the synthetic lethality pipeline.

Aprea Therapeutics News

Aprea Therapeutics files to sell 5.5M shares of common stock for holders

16:15 EST Aprea Therapeutics (APRE) files to sell 5.5M shares of common stock for holders Published first on...

7h ago

APRE

Aprea Therapeutics price target lowered to $5 from $20 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Aprea Therapeutics (APRE) to $5 from $20 and keeps a...

2d ago

APRE

Aprea Therapeutics CEO issues letter to shareholders

Aprea Therapeutics (APRE) issued the following letter to shareholders from Chief Executive Officer, Oren Gilad. The letter highlights...

2d ago

APRE

Aprea Therapeutics prices 2.62M shares at $1.165 in private placement

Aprea Therapeutics (APRE) entered into a securities purchase agreement with new and existing healthcare focused investors and certain...

11d ago

APRE

Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics, reducing the price target to...

23h ago

APRE

Aprea Therapeutics Secures $3.1M in Private Placement

Aprea Therapeutics ( ($APRE) ) just unveiled an update. On December 8, 2025, Aprea Therapeutics entered into a...

10d ago

APRE

Aprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Aprea Therapeutics, retaining the price target of...

1M ago

APRE

Aprea Therapeutics Reports Ongoing Financial Challenges

Aprea Therapeutics, Inc. ( ($APRE) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

APRE

Aprea Therapeutics Reports Q3 Results and Clinical Updates

The latest announcement is out from Aprea Therapeutics ( ($APRE) ). On November 12, 2025, Aprea Therapeutics reported...

1M ago

APRE

Aprea Therapeutics reports Q3 EPS (47c) vs. (64) last year

“We are pleased with the continued progress in our development programs, as the emerging data on both of...

1M ago

APRE

Aprea Therapeutics sees cash runway into 4Q26

As of September 30, 2025, the Company reported cash and cash equivalents of $13.7 million compared to $22.8...

1M ago

APRE

Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors

Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. is conducting a...

2M ago

APRE

Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors

Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. is conducting a...

2M ago

APRE

Aprea Therapeutics Reports Promising Trial Results for APR-1051

The latest update is out from Aprea Therapeutics ( ($APRE) ). On October 24, 2025, Aprea Therapeutics announced...

2M ago

APRE

APRE FAQ

What was Aprea Therapeutics Inc’s price range in the past 12 months?

Aprea Therapeutics Inc lowest stock price was $0.90 and its highest was $5.00 in the past 12 months.

What is Aprea Therapeutics Inc’s market cap?

Aprea Therapeutics Inc’s market cap is $5.74M.

When is Aprea Therapeutics Inc’s upcoming earnings report date?

Aprea Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 96 days.

How were Aprea Therapeutics Inc’s earnings last quarter?

Aprea Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.13.

Is Aprea Therapeutics Inc overvalued?

According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aprea Therapeutics Inc pay dividends?

Aprea Therapeutics Inc does not currently pay dividends.

What is Aprea Therapeutics Inc’s EPS estimate?

Aprea Therapeutics Inc’s EPS estimate is -0.4.

How many shares outstanding does Aprea Therapeutics Inc have?

Aprea Therapeutics Inc has 6,310,673 shares outstanding.

What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?

Aprea Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -4.545%.

Which hedge fund is a major shareholder of Aprea Therapeutics Inc?

Currently, no hedge funds are holding shares in APRE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics (APRE) Earnings & Revenues

Historic Earnings Reports

APRE Stock 12 Month Forecast

Average Price Target

$7.50

▲(724.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.7938461538461539,2.477692307692308,3.161538461538462,3.8453846153846154,4.52923076923077,5.213076923076923,5.896923076923078,6.580769230769231,7.264615384615385,7.948461538461539,8.632307692307693,9.316153846153846,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.6015384615384616,2.0930769230769233,2.5846153846153848,3.0761538461538462,3.567692307692308,4.059230769230769,4.550769230769231,5.042307692307692,5.533846153846154,6.025384615384616,6.516923076923077,7.008461538461539,{"y":7.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.11,1.4092307692307693,1.7084615384615385,2.0076923076923077,2.306923076923077,2.606153846153846,2.905384615384615,3.2046153846153844,3.503846153846154,3.8030769230769232,4.102307692307692,4.401538461538461,4.700769230769231,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.77,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >